Vanguard Group Inc. Acquires 347,074 Shares of BridgeBio Pharma, Inc. $BBIO

Vanguard Group Inc. lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 16,832,059 shares of the company’s stock after purchasing an additional 347,074 shares during the quarter. Vanguard Group Inc. owned about 8.73% of BridgeBio Pharma worth $874,257,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BBIO. Geode Capital Management LLC boosted its holdings in shares of BridgeBio Pharma by 5.1% in the second quarter. Geode Capital Management LLC now owns 3,681,580 shares of the company’s stock valued at $158,991,000 after buying an additional 178,686 shares during the period. Invesco Ltd. lifted its position in BridgeBio Pharma by 27.0% in the 2nd quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock valued at $120,950,000 after acquiring an additional 594,902 shares in the last quarter. Norges Bank acquired a new position in BridgeBio Pharma in the 2nd quarter worth $84,488,000. Principal Financial Group Inc. increased its holdings in BridgeBio Pharma by 23.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of BridgeBio Pharma by 6.1% in the 2nd quarter. American Century Companies Inc. now owns 1,090,134 shares of the company’s stock valued at $47,072,000 after purchasing an additional 62,646 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the completion of the sale, the director directly owned 11,589 shares in the company, valued at approximately $874,505.94. This represents a 46.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $74.26, for a total value of $148,520.00. Following the transaction, the chief accounting officer directly owned 130,297 shares of the company’s stock, valued at $9,675,855.22. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 176,121 shares of company stock worth $13,009,631 in the last quarter. Insiders own 18.20% of the company’s stock.

BridgeBio Pharma Stock Down 3.6%

Shares of BridgeBio Pharma stock opened at $68.14 on Monday. The stock has a market capitalization of $13.13 billion, a price-to-earnings ratio of -16.30 and a beta of 1.13. BridgeBio Pharma, Inc. has a twelve month low of $28.33 and a twelve month high of $84.94. The company has a 50-day simple moving average of $75.52 and a two-hundred day simple moving average of $64.22.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BBIO shares. Oppenheimer upped their price objective on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Morgan Stanley started coverage on BridgeBio Pharma in a research report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target for the company. Piper Sandler lifted their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Barclays started coverage on shares of BridgeBio Pharma in a report on Wednesday, January 28th. They set an “overweight” rating for the company. Finally, HC Wainwright upped their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $82.05.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results improve the commercial and regulatory outlook for BridgeBio’s achondroplasia program — a fundamental driver for longer‑term upside. PROPEL 3 Results
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and boosted its price target to $100 while maintaining a Buy — analyst upgrades can support buying interest and help re‑rate shares if fundamentals continue to improve. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst coverage remains constructive (multiple Buy/Overweight ratings and higher targets), which can amplify rallies following positive clinical/financial news. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this is the next near‑term catalyst that could drive volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to new hires (~76,701 shares aggregate) — modest ongoing share‑based comp that could be a small dilution factor to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer reported a small new 13F position (~7,845 shares) — modest institutional interest but not yet material to the register. Oppenheimer 13F
• Neutral Sentiment: Short‑interest reporting for Feb. 19 shows anomalous/zero values in the feed (likely a data/reporting glitch) — no clear evidence of a meaningful short squeeze or build from this item alone.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal W. Scott sold 10,000 shares and senior officers (CFO and CAO) also disclosed sales (CFO ~13,600 shares; CAO 510 shares) — concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Ongoing pattern of executive liquidity events highlighted in reporting — repeated insider selling can keep downward pressure on the stock until insiders demonstrate renewed accumulation. Insider/Sentiment Summary

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.